What is Refocus Group?
Founded in 1994 and headquartered in Dallas, Texas, Refocus Group is a medical device company dedicated to the research and development of treatments for presbyopia. The company's flagship innovation, the VisAbility Micro-Insert System, is currently an investigational medical device undergoing rigorous clinical evaluation. By targeting the binocular presbyopic treatment market, Refocus Group occupies a critical niche in the healthcare sector, bridging the gap between traditional vision correction and surgical intervention.
The company's operational model is centered on long-term clinical validation and the development of high-impact medical technologies. As a mature entity in the medical device space, Refocus Group maintains a focus on delivering value to both patients and eye care practitioners through evidence-based research and strategic product development.
How much funding has Refocus Group raised?
Refocus Group has raised a total of $15.3M across 2 funding rounds:
Unspecified
$15M
Debt
$350K
Unspecified (2016): $15M with participation from MedCare Investment Funds and WP Global Partners
Debt (2020): $350K led by PPP
Key Investors in Refocus Group
MedCare Investment Funds
A private investment firm managing approximately $1 billion in assets, specializing in the medical and healthcare services industry with a focus on both capital appreciation and long-term business growth.
WP Global Partners
An investment firm that utilizes a hybrid strategy of primary fund commitments and direct investments to support small and medium-sized enterprises essential to economic growth.
PPP
Public-Private Partnership
What's next for Refocus Group?
Looking ahead, the recent capital injection is expected to accelerate the clinical trial trajectory for the VisAbility Micro-Insert System. As the company moves toward potential commercialization, the focus will likely shift from research-heavy operations to scaling manufacturing and establishing robust distribution channels. The strategic backing received provides the necessary runway to navigate the final stages of regulatory approval, a critical hurdle for any medical device firm operating in the vision correction space.
Furthermore, the company is positioned to leverage its existing intellectual property to explore broader applications within the ophthalmology market. By maintaining a disciplined approach to capital allocation, Refocus Group aims to solidify its market position, ensuring that its technological advancements translate into sustainable growth and improved patient outcomes in the global vision care industry.
